Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: J Consult Clin Psychol. 2014 Jul 7;82(6):1034–1048. doi: 10.1037/a0037212

Table 3.

Estimated slopes (change) from Pre to Post treatment (S1) and post to 12MFU (S2), and effect sizes (Cohen’s d) for pair-wise group slope comparisons for CBT vs. ACT, ACT vs. WL and CBT vs. WL

CBT ACT WL CBT
vs.
ACT
vs.
CBT
vs.
beta (95% CI) beta (95% CI) beta (95% CI) ACT
d12
WL
d
WL
d

SYMPTOMS

Composite Symptom Scale
S1 −1.0 (−1.3 to −.7)*** −1.1 (−1.4 to −0.8)*** −0.2 (−0.5 to 0.1) 0.11 .97 1.02
S2 −0.1 (−0.3 to 0.0) 0.0 (−0.2 to 0.1) -- 0.23 -- --
Clinical Severity Rating
S1 −2.4 (−3.0 to −1.9)*** −1.8 (−2.4 to −1.2)*** −0.3 (−0.9 to 0.3) 0.62 1.51 2.19
S2 0.0 (−0.3 to 0.4) −0.1 (−0.4 to 0.2) -- 0.16 -- --
Fear & Avoidance Ratings
S1 −32.6 (−44.1 to −21.2)*** −21.8 (−33.2 to −10.3)*** −3.8 (−15.8 to 8.2) .43 .60 1.04
S2 −1.5 (−7.1 to 4.1) −5.0 (−10.2 to 0.2) -- .31 -- --

QUALITY OF LIFE

QOLI (higher numbers indicate improvement)
S1 0.4 (−0.1 to 0.9) 0.1 (−0.4 to 0.5) 0.1 (−0.4 to 0.6) 0.23 0.00 0.26
S2 0.0 (−0.2 to 0.3) 0.2 (−0.1 to 0.5) -- 0.17 -- --

PUBLIC SPEAKING

SUDS during speech
S1 −26.6 (−38.3 to −14.8)*** −22.7 (−33.9 to −11.6)*** −16.3 (−27.9 to −4.8)** 0.15 0.26 0.44
S2 3.9 (−3.0 to 10.9) −5.4 (−11.8 to 1.0) -- 0.80 -- --
HHS Vulnerability Disclosure